Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Gains from Sales and Divestitures: 2009-2017

Historic Gains from Sales and Divestitures for Cytokinetics (CYTK) over the last 2 years, with Dec 2017 value amounting to $171,250.

  • Cytokinetics' Gains from Sales and Divestitures rose 274.32% to $171,250 in Q4 2017 from the same period last year, while for Dec 2017 it was $171,250, marking a year-over-year increase of 274.32%. This contributed to the annual value of $171,250 for FY2017, which is 274.32% up from last year.
  • Cytokinetics' Gains from Sales and Divestitures amounted to $171,250 in Q4 2017, which was up 274.32% from $45,750 recorded in Q4 2016.
  • Over the past 5 years, Cytokinetics' Gains from Sales and Divestitures peaked at $211,897 during Q3 2013, and registered a low of $20,833 during Q4 2014.
  • In the last 3 years, Cytokinetics' Gains from Sales and Divestitures had a median value of $45,750 in 2016 and averaged $86,359.
  • Per our database at Business Quant, Cytokinetics' Gains from Sales and Divestitures crashed by 90.17% in 2014 and then skyrocketed by 274.32% in 2017.
  • Over the past 5 years, Cytokinetics' Gains from Sales and Divestitures (Quarterly) stood at $211,897 in 2013, then crashed by 90.17% to $20,833 in 2014, then spiked by 101.98% to $42,078 in 2015, then increased by 8.73% to $45,750 in 2016, then skyrocketed by 274.32% to $171,250 in 2017.
  • Its Gains from Sales and Divestitures stands at $171,250 for Q4 2017, versus $45,750 for Q4 2016 and $42,078 for Q4 2015.